EVANSVILLE, IN - June 16, 2008 - Covance Inc., (NYSE: CVD) the world’s largest publicly-traded contract research organization, announced today that it has relocated and significantly upgraded its clinical pharmacology research unit in Evansville, Indiana. The $12.4 million stand-alone, purpose-built facility is a premier clinical research unit for conducting first-in-human studies and other complex trials requiring special attention.
The completion of the 50,000 square-foot Evansville facility caps a two-year clinic investment program which included upgraded facilities for clinical research units in Austin, Texas; Daytona Beach, Florida; and Honolulu, Hawaii.
“Our new clinic is truly a top-tier research facility,” says Mary Westrick, Vice President and General Manager of Global Clinical Pharmacology. “In addition to our experienced medical team on-site, we can now provide our clients and patients with the safety of around-the-clock emergency response, including Code Blue, from Deaconess Hospital.”
Located on the campus of Deaconess Hospital, the new facility features a USP 797-compliant pharmacy for sterile compounding, a large on-site CLIA laboratory for immediate turnaround of human lab samples, and a hospital-like audible emergency call system for patient safety. The Evansville clinic has a database of approximate 41,000 volunteers for participation in Phase I trials.
“We are very excited to introduce our staff and volunteers to the new facility,” says Launa Mitchell, Site Director. “Our volunteers will particularly notice the increased levels of comfort and amenities, including an outdoor terrace, two large lounges, wireless Internet and larger patient rooms with TV/VCR/DVD combos.”
Covance offers early stage testing at ten clinical sites in the United States and United Kingdom. To learn more about clinical research services at Covance, please call 888-COVANCE (888-268-2623) in the Americas; 44(0)4235-00888 in Europe; or 1-65-65677333 in Asia or visit our website at www.covance.com.
